The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advancements in bispecific and trispecific antibodies for the treatment of lymphoma
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current landscape and future directions of bispecific antibodies for treating follicular lymphoma (FL) and large B-cell lymphoma (LBCL), highlighting promising new targets such as CD19. He also notes the development of trispecific antibodies and other strategies to engage immune cells beyond T-cells, with emerging data expected in upcoming meetings. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Genentech/Roche, ADC Therapeutics, TG Therapeutics, Kite, a Gilead company. Research Funding: AstraZeneca, ALX Oncology, Gilead Sciences. Travel, Accommodations, Expenses: SOBI.
